Clinical trials: Renal Transplant Recipient
Sexual Dysfunction
Sexual Dysfunction After Renal Transplantation
A questionnaire will be send to kidney transplant recipients to investigate characteristics of them and their sexual function, all participants in the survey are anonymous and voluntary, then analyse these characteristics.
- Trial name
- NCT05856929
- Testing
- no Intervention
- Where
- 2 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Kidney Transplantation, Cardiovascular Diseases
Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients
The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of…
- Trial name
- MMCR (NCT01213394)
- Testing
- mycophenolate mofetil, standard immunosuppression
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ramesh Prasad
Kidney Transplant Recipients
An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients
To evaluate whether maintenance renal transplant patients on micophenolate mofetil (MMF) can be safely converted to EC-MPS, based on adverse events and acute rejection within 6 months after switching from MMF to a EC-MPS regimen.
- Trial name
- NCT00239044
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Transplant; Failure, Kidney
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
- Trial name
- NCT01163799
- Testing
- Alefacept (ASP0485)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Renal Transplantation
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
Clinical trial for the novo transplant recipients, which aims to assess tolerability and safety and clinical outcomes of EC-MPS in combination with cyclosporine microemulsion (CsA-ME) with or without steroids in a population of…
- Trial name
- NCT00238953
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Kidney Transplant; Complications, Toxicity
Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related…
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Trial name
- NCT03461445
- Testing
- Envarsus, IR Tacrolimus
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Davis
De Novo Renal Transplant Recipient.
Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation
Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared with fixed dosing in de novo MMF treated renal transplant recipients with respect to the incidence of treatment failure.
- Trial name
- NCT00166244
- Testing
- Mycophenolate Mofetil
- Where
- 67 sites in Australia, Austria and 17 more
- Volunteers
- 901 people
- Sponsor
- Erasmus Medical Center
Kidney Transplantation
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
The purpose of this study is to evaluate the efficacy and safety of ASKP1240, an anti-CD40 monoclonal antibody, for the prophylaxis of organ rejection after kidney transplantation.
- Trial name
- NCT01780844
- Testing
- ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF)
- Where
- 42 sites in United States
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Latent Tuberculosis Infection
Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients
Interferon gamma release assays (IGRA) have been shown to be more specific and sensitive for the detection of tuberculosis (latent or active infection) than the tuberculin skin test (TST) in immunocompetent individuals.
- Trial name
- NCT01608685
- Where
- Switzerland
- Volunteers
- 205 people
- Sponsor
- Ligue Pulmonaire Genevoise
Liver Transplant Infection, Kidney Transplant Infection
Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant
This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible…
- Conditions
- Liver Transplant Infection, Kidney Transplant Infection, Liver Transplant, Kidney Transplant
- Trial name
- PREVENT (NCT07651137)
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Antibody-mediated Rejection
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure.
- Trial name
- TRANSCEND (NCT06685757)
- Testing
- Felzartamab
- Where
- 56 sites in United States, Argentina and 10 more
- Volunteers
- 132 people
- Sponsor
- Biogen
Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in Kidney Transplant Recipients in India
To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.
- Trial name
- NCT00195481
- Testing
- Rapamune
- Where
- 5 sites in India
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Disorder Related to Renal Transplantation
Steroid Withdrawal Immunosuppression After Renal Transplantation
The investigators analyze the clinical outcome of steroid withdrawal protocol starting at 3 months after kidney transplantation using tacrolimus, Mycophenolate Mofetil (MMF), and basiliximab.
- Trial name
- NCT01550445
- Testing
- Prednisolone
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Ajou University School of Medicine
Kidney Transplant
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment…
- Trial name
- NCT03644485
- Testing
- Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy
- Where
- 14 sites in China
- Volunteers
- 284 people
- Sponsor
- Astellas Pharma China, Inc.
De Novo Kidney Transplant
MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive
To prospectively evaluate in de novo kidney transplant recipients, hepatitis C positive, the clinical outcomes of an immunosuppressive regimen of EC-MPS free of steroids in comparison with a regimen of EC-MPS with standard…
- Trial name
- NCT00284921
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Graft Failure, Death
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate…
- Conditions
- Graft Failure, Death, Acute Rejection of Renal Transplant, Infections
- Trial name
- SENIOR (NCT02558452)
- Testing
- Tacrolimus once daily (Advagraf)
- Volunteers
- 1,000 people
- Sponsor
- Klemens Budde
Renal Anemia
Variability of Hemoglobin Levels After Kidney Transplantation
The purpose of this study es to determine hemoglobin variability in kidney transplant recipients with chronic renal anemia.
- Trial name
- NCT02041208
- Testing
- kidney transplantation
- Where
- 22 sites in Spain
- Volunteers
- 368 people
- Sponsor
- Sociedad Española de Trasplante
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland